PT  - JOURNAL ARTICLE
AU  - Català-Senent, José F.
AU  - Hidalgo, Marta R.
AU  - Berenguer, Marina
AU  - Malhi, Harmeet
AU  - García-García, Francisco
TI  - Sex differences in the progression from NAFL to NASH: a functional meta-analysis of transcriptomic studies
AID  - 10.1101/2020.06.03.20118570
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.03.20118570
4099  - http://medrxiv.org/content/early/2020/06/05/2020.06.03.20118570.short
4100  - http://medrxiv.org/content/early/2020/06/05/2020.06.03.20118570.full
AB  - Background & aims Sex differences in non-alcoholic fatty liver disease (NAFLD) are well known and yet, most of the studies available in the literature do not include this factor when analysing the data. Here we present a functional meta-analysis of NAFLD studies to detect the molecular mechanisms involved in its progression, distinguishing any differences relative to patient sex.Methods We systematically reviewed the Gene Expression Omnibus (GEO) database functional Gene Ontology (GO) terms detailed in transcriptomic studies, following the PRISMA statement guidelines. For each study, we compared the progression from steatosis (NAFL) to steatohepatitis (NASH) in premenopausal women and men using a dual strategy: a gene-set analysis and a pathway activity analysis. The functional results of all the studies were integrated in a meta-analysis used to detect functions that were differentially affected in these groups, according to these two methods.Results A total of 105 abstracts were reviewed and 7 studies, which included 624 patients, were finally analysed. The meta-analyses highlighted significant functions in both sexes. In premenopausal women, the overrepresented functions referred to DNA regulation, vinculin binding, interleukin 2 (IL-2) responses, negative regulation of neuronal death, and the transport of ions and cations. In men, they referred to the negative regulation of IL-6 and the establishment of planar polarity involved in neural tube closure.Conclusions Our meta-analysis of this transcriptomic data provides a powerful approach to identify sex differences in the progression from NAFL to NASH. We detected relevant biological functions and molecular terms that were affected differently between premenopausal women and men. Changes in the immune responsiveness between men and women with NAFLD suggested that women have a more immune tolerant milieu while men have an impaired liver regenerative response. These results open the door to more pathophysiological studies into the differential role of IL-2 and IL-6 in NAFLD, and eventually to personalised treatments for this disease.Lay summary Progression from NAFL to NASH differently affects cellular functions in women and men. Here we systematically reviewed publicly available transcriptomic data and then performed a meta-analysis to find these affected functions. Thus, we identified 13 biological functions implicated in the progression of NAFLD that were differentially affected by sex.HighlightsTranscriptomics meta-analysis detects significant sex differences in NAFLD progression.Interleukins 2 and 6 are upregulated in premenopausal women compared to men.Changes in the immune responsiveness may explain the sex-differences observed.Sex differences need to be taken into account in the NAFLD studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Principe Felipe Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This paper has used data from previously published studies and is therefore exempt from further ethics committee approvals.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis work uses data published in previous studies, which is available in the Gene Expression Omnibus repository. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48452 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61260 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66676 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83452 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89632 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126848 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130970